Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718330 | 0.81 | PTGER1 (0.49) | BRD4NPC1PTGER1 | |
| SCHEMBL4715074 | 0.75 | NPSR1 (0.50) | BRD4NPC1PTGER1 | |
| SCHEMBL29514421 | 0.73 | PKM (0.44) | ADORA3MAPK14BRD4KDM1ANPC1 | |
| SCHEMBL22748471 | 0.73 | PKM (0.44) | ADORA3MAPK14BRD4KDM1ANPC1 | |
| SCHEMBL4716863 | 0.72 | PTGER1 (0.45) | BRD4NPC1PTGER1 | |
| SCHEMBL4267531 | 0.69 | MRGPRX4 (0.63) | LTA4HMAPK14KDM1AHTR1ASLC6A2 | |
| SCHEMBL2894699 | 0.68 | KDM1A (0.57) | LTA4HMAPK14KDM1AHTR1ASLC6A2 | |
| SCHEMBL4715703 | 0.66 | MAPK14 (0.45) | MAPK14ROCK1 | |
| SCHEMBL31710188 | 0.66 | MAPK14 (0.45) | MAPK14ROCK1 | |
| SCHEMBL4455302 | 0.66 | ADORA1 (0.47) | ADORA3MAPK14ADORA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050032820-A1 | Novel spiro compounds | MSD K.K. (JP) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032820-A1 | Novel spiro compounds | NR3C2, GPR119, NPY2R | ADORA3 2951/4885LTA4H 1492/4885MAPK14 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.